9 Best Psychedelic Stocks to Buy in 2026
The AdvisorShares Psychedelics ETF, a fund that primarily invests in the psychedelic drugs sector, is up 31% over the past year. That almost doubles the S&P 500’s 16% gain over the same timeframe.
Bright Minds Biosciences Inc. (DRUG)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Cormorant Asset Management Bihua Chen | 1,059,331 | $77,299,383 | 3.88% | |
| 2. | Vivo Capital Albert Cha And Frank Kung | 557,172 | $40,656,841 | +12% | 3.38% |
| 3. | Braidwell LP Alex Karnal | 539,708 | $39,382,493 | +67% | 1.31% |
| 4. | Adage Capital Management Phill Gross And Robert Atchinson | 495,743 | $36,174,367 | +26% | 0.06% |
| 5. | Vestal Point Capital Ryan Wilder | 492,319 | $35,924,517 | 1% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $21.70 | 184,331 | $3,999,982.70 | 1,059,331 | 2024-11-04 | Filing | |
| $25.22 | 3,107 | $78,364.75 | 875,000 | 2024-10-16 | Filing | |
| $24.03 | 7,150 | $171,814.50 | 871,893 | 2024-10-16 | Filing | |
| $23.22 | 39,743 | $922,633.75 | 864,743 | 2024-10-16 | Filing | |
| $12.35 | 4,609 | $56,927.14 | 825,000 | 2024-10-15 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $89.50 | 109,331 | $9,785,124.50 | 950,000 | 2026-04-28 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,284,324 | $93,518,052 | 0.04% | |
| 2. | 621,933 | $45,382,452 | 0% | |
| 3. | 136,677 | $9,973,321 | 0% | |
| 4. | 132,764 | $9,687,828 | 0% | |
| 5. | 130,013 | $9,487,049 | 0.16% |
News See All
Baird Lowers Bright Minds Biosciences Inc. (DRUG) Price Target to $126, Maintains Outperform Rating Ahead of Upcoming Trials
TheFly reported on February 13 that Baird lowered its price target for DRUG to $126 from $142 and maintained an Outperform rating on the shares.
7 Most Promising Psychedelic Stocks According to Hedge Funds
The psychedelic industry is poised to have a significant "second wave," transforming from a speculative, counterculture-driven movement into a recognized cornerstone of the US healthcare system.
Bright Minds Biosciences Inc. (DRUG) Advances Phase 2 Trial for Drug-Resistant Epilepsy
Bright Minds Biosciences Inc. (NASDAQ:DRUG) is a biotechnology company developing highly selective 5-HT2 agonists to treat drug-resistant epilepsy, depression, and other CNS disorders.
13 Best Psychedelic Stocks to Invest in Now
Unlike drugs such as cocaine or marijuana, psychedelics create an “alternate reality” by altering feelings, thoughts, and energy levels.
Hedge Fund Resource Center